These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Development of a new live attenuated Leishmania major p27 gene knockout: Safety and immunogenicity evaluation in BALB/c mice. Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR Cell Immunol; 2018 Oct; 332():24-31. PubMed ID: 30053997 [TBL] [Abstract][Full Text] [Related]
7. Canine Leishmania vaccines: still a long way to go. Gradoni L Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis. Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085 [TBL] [Abstract][Full Text] [Related]
9. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291 [TBL] [Abstract][Full Text] [Related]
10. LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis. Aguiar-Soares RD; Roatt BM; Ker HG; Moreira Nd; Mathias FA; Cardoso JM; Gontijo NF; Bruna-Romero O; Teixeira-Carvalho A; Martins-Filho OA; Corrêa-Oliveira R; Giunchetti RC; Reis AB Parasit Vectors; 2014 Feb; 7():61. PubMed ID: 24507702 [TBL] [Abstract][Full Text] [Related]
11. Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran. Daneshvar H; Namazi MJ; Kamiabi H; Burchmore R; Cleaveland S; Phillips S PLoS Negl Trop Dis; 2014 Apr; 8(4):e2757. PubMed ID: 24743691 [TBL] [Abstract][Full Text] [Related]
12. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Carrión J; Folgueira C; Soto M; Fresno M; Requena JM Parasit Vectors; 2011 Jul; 4():150. PubMed ID: 21794145 [TBL] [Abstract][Full Text] [Related]
13. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199 [TBL] [Abstract][Full Text] [Related]
14. Immunoprophylactic Potential of a New Recombinant Pessoa-E-Silva R; Trajano-Silva LAM; Vaitkevicius-Antão V; Dos Santos WJT; Magalhães FB; Moura DMN; Nakasone EKN; de Lorena VMB; de Paiva-Cavalcanti M Front Immunol; 2020; 11():605044. PubMed ID: 33488607 [TBL] [Abstract][Full Text] [Related]
15. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731 [TBL] [Abstract][Full Text] [Related]
16. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis. Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513 [TBL] [Abstract][Full Text] [Related]
17. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation. Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161 [TBL] [Abstract][Full Text] [Related]
18. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553 [TBL] [Abstract][Full Text] [Related]
19. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species. Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272 [TBL] [Abstract][Full Text] [Related]
20. Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates. Grimaldi G; Teva A; Dos-Santos CB; Santos FN; Pinto ID; Fux B; Leite GR; Falqueto A PLoS One; 2017; 12(9):e0185438. PubMed ID: 28953944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]